FDA greenlights 23andMe’s direct-to-consumer cancer risk test

23andMe had previously offered genetic health risk tests, but suspended them in order to get FDA approval. The agency had greenlit disease and deficiency-related health risk tests in 2017, and had streamlined its approval process later that same year. The company is quick to warn that this test doesn’t rule out cancer, and won’t diagnose …

Continue reading “FDA greenlights 23andMe’s direct-to-consumer cancer risk test”